Skip to main content

Table 2 Disease activity in patients with residual disease activity resulting or not resulting in additional treatment

From: Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice

  Total group
(n = 90)
Additional treatment (n = 21) No additional treatment (n = 69) Additional treatment vs No additional treatment P value
Age, mean (SD) 53.6 (12.2) 52.6 (10.8) 53.9 (12.7) 0.270
Male/female, n/n 53/37 15/6 38/31 0.167
Disease duration diagnosis mean, (SD) 11.0 (9.2) 10.8 (8.6) 11.2 (9.4) 0.837
On treatment > 6 months, % 92 90 93 0.057
Swollen joints 0 (-0–1) 0 (0–1.5) 0 (0–1) 0.359
SJC of 0, n (%) 63 (70) 13 (62) 50 (72)  
SJC of 1, n (%) 8 (9) 3 (14) 5 (7)
SJC of 2, n (%) 5 (6) 2 (10) 3 (4)
SJC of ≥3, n (%) 14 (16) 3 (14) 11 (16)
Tender joints 1 (0–3) 1 (0–2) 1 (0–3) 0.923
TJC of 0, n (%) 36 (40) 7 (33) 29 (42)
TJC of 1, n (%) 16 (18) 8 (38) 8 (12)
TJC of 2, n (%) 12 (13) 2 (10) 10 (15)
TJC of ≥3, n (%) 25 (27) 4 (20) 21 (30)
Number of dactylitic digits 0 (0–0) 0 (0–0) 0 (0–0) 0.310
Dactylitic digits ≥1, n (%) 8 (9) 3 (14) 5 (8)  
Number of enthesitis points 0 (0–0) 0 (0–0) 0 (0–0) 0.384
Enthesitis points ≥1, n (%) 16 (18) 5 (24) 11 (16)
VAS physician skin severity 1 (1–3) 2 (1–3.5) 1 (1–2) 0.478
VAS physician overall disease activity 2 (1–4) 3 (2–5) 2 (1–3) 0.007
VAS patient global disease activity 5 (2–7) 6 (3–7) 5 (2–7) 0.157
VAS pt pain 5 (2–7) 6 (3–7) 4 (2–7) 0.225
BASDAI 4.1 (2.5–5.9) 4.2 (2.7–5.8) 3.7 (2.5–5.9) 0.907
cDAPSA remission, n (%) 9 (10) 1 (5) 8 (12) 0.594
cDAPSA low disease activity, n (%) 34 (38) 7 (33) 27 (39)  
cDAPSA moderate disease activity, n (%) 35 (39) 11 (52) 23 (33)  
cDAPSA high disease activity, n (%) 6 (7) 2 (10) 4 (6)  
cDAPSA missing, n (%) 6 (7) 0 6 (9)  
  1. Numbers are median (IQR) unless stated otherwise. Significance of the comparisons is determined by independent sample t test for continues variables and the Mann-Whitney U test for non-normally distributed variables. The comparisons within the cDAPSA groups were determined by the Kruskall-Wallis test
  2. SJC swollen joint count, TJC tender joint count, VAS visual analog scale, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, cDAPSA clinical Disease Activity in PsA score